Comparison of Erythritol Air-Polishing and Conventional Polishing Following Ultrasonic Scaling on the Relapse of Chromogenic Tooth Staining in Children

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age4-13
SponsorMarmara University

About this trial

The goal of this randomized clinical trial is to compare the effect of erythritol air-polishing and conventional polishing following ultrasonic scaling on the relapse of chromogenic tooth staining in children aged 4-13 years attending the Pediatric Dentistry Clinic of Marmara University Faculty of Dentistry for routine dental examination.

The main questions this study aims to answer are:

* Does erythritol air-polishing reduce the relapse of chromogenic tooth staining compared with conventional polishing following ultrasonic scaling? * Is there a difference in the time to relapse of chromogenic tooth staining between the two polishing techniques?

Researchers will compare conventional polishing (prophylaxis paste and a polishing brush) following ultrasonic scaling with erythritol air-polishing performed using the EMS air-polishing device following ultrasonic scaling to determine whether one method is more effective in preventing or delaying the relapse of chromogenic tooth staining.

Eligibility criteria

Qualifiers

Children aged 4-13 years.

Absence of oral diseases, including gingivitis and oral mucosal diseases.

No orthodontic appliances.

No history of iron supplementation or professional fluoride treatment within the previous 3 months.

Disqualifiers

Presence of oral diseases, including periodontitis, salivary gland diseases, or oral mucosal diseases.

History of autoimmune disease.

Antibiotic use within the previous 3 months.

Consumption of tannin-containing beverages (e.g., tea, coffee, or similar beverages) within the previous 1 month.

Trial design

Treatments tested in this trial

  • Guided Biofilm Therapy with erythritol
  • Conventional Polishing

Treatment groups

56 Participants
are divided into 2 treatment groups

Sponsors and collaborators